On the other hand, by activating the non-canonical NFkB pathway, LCL161 has been shown to manipulate the tumor microenvironment inducing immune activation and resulting in long-lasting protection against myeloma progression in vivo [12]. This evidence concerns the gene NFKB1 and plasma cell myeloma.